Back to top
more

Merck & Co., Inc. (MRK)

(Real Time Quote from BATS)

$84.19 USD

84.19
5,111,194

+0.91 (1.09%)

Updated Nov 12, 2019 03:47 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.51%
17.57%
9.27%
4.95%
1.80%
10.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | A Growth | D Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Merck's Ebola Vaccine Gets Conditional Approval in Europe

European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

MRK GSK REGN INO

Zacks Equity Research

Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review

Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.

MRK BMY BAYRY RHHBY

Zacks Equity Research

Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

PFE MRK BMY AZN

Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health

MRK QCOM UNH CVS MA

Zacks Equity Research

Novartis' Generics Unit to Buy Aspen's Japanese Operations

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

MRK BMY NVS GSK

Zacks Equity Research

Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

MRK NVS LLY ADRO

Zacks Equity Research

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

MRK RTRX DERM LHCG

Mark Vickery

Top Analyst Reports for Mastercard, UnitedHealth & Merck

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), UnitedHealth Group (UNH) and Merck (MRK).

UNH QCOM MRK MA DHR CVS

Zacks Equity Research

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.

MRK LLY BMY NKTR

Zacks Equity Research

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

MRK ACOR VRTX ESPR

Zacks Equity Research

Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.

MRK RTRX DERM LHCG

Sanghamitra Saha

Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

ABBV BMY MRK RHHBY LLY GSK XBI BBH AMGN BIIB CELG IDNA

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

PFE GSK MRK BMY

Zacks Equity Research

Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

ABBV GSK MRK RDY

Zacks Equity Research

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.

MRK GSK ABBV NVO

Kinjel Shah

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

BMY MRK PFE GSK JNJ ABBV SNY

Zacks Equity Research

Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss

The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.

MRK ALNY MDCO ACOR

Zacks Equity Research

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.

RHHBY PFE MRK EXEL

Zacks Equity Research

Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

RHHBY MRK SGEN TAK

Zacks Equity Research

Stock Market News For Oct 30, 2019

Benchmarks closed in the negative territory on Tuesday due to Alphabet???s weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.

VRSK GOOGL PFE MRK CXO ADP

Sweta Killa

Healthcare ETFs Win in October: Here's Why

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

PFE MRK IHF XBI SBIO BBC XPH BIIB ALXN ACHN HEPA GNOM

Zacks Equity Research

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?

Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.

NVS MRK BMY CELG

Zacks Equity Research

Strong Q3 Earnings Data Deluge

Strong Q3 Earnings Data Deluge

MRK PFE GM MA

Zacks Equity Research

Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View

Merck (MRK) beats estimates for earnings as well as sales in third-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.

BAYRY JNJ MRK AZN

Mark Vickery

Q3 Earnings Bonanza: GM, MRK, MA & More

GM fought through strike headwinds to beat estimates, Merck's cancer drug performs great, and Pfizer and Mastercard beat, too.

PFE MRK GM MA